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A B S T R A C T
Purpose: This study aims to examine the correlation between sexual function and sexual distress, and to de-
termine the predictive factors of sexual function and sexual distress in women with gynecologic cancers.
Methods: In this cross-sectional study, 387 subjects were referred to Velayat Hospital in Qazvin, Iran, using
convenience sampling method between June and August 2016. Data were collected using a demographic
questionnaire, the Female Sexual Function Index (FSFI), and the Female Sexual Distress Scale-Revised (FSDS-R).
Results: Mean scores of sexual function and sexual distress were 19.4 ± 6.7 and 29.2 ± 12.9, respectively.
There was no signiﬁcant correlation between sexual function and sexual distress. Multivariate predictors of FSFI
were cancer stage (p=0.023), cancer type (p=0.025), duration of disease (β=−0.10, 95% CI [-0.17, – 0.02],
p=0.017) and social support (β=0.53, 95% CI [0.24, 0.83], p < 0.001). Predictors of FSDS-R were economic
status (p=0.040) and type of cancer (p=0.016). There was a negative relation between the overall score on
FSDS-R and FSFI sub domains of desire (β=−1.4, p=0.033) and arousal (β=−2.1, p=0.024).
Conclusions: This study did not support a relation between sexual function and sexual distress. Other factors,
however, including cancer type, economic status and social support may aﬀect sexual function and sexual
distress. Future studies needed to determine further factors which can aﬀect the sexual distress and sexual
function of gynecologic cancer patients.
1. Introduction
Cancer is a major public health problem worldwide and is the
second leading cause of death in the United States (Siegel et al., 2016).
In Iran, cancer is one of the most common diseases in the 21st century
and is the third most common cause of death, after cardiovascular
disease and accidents (Saadat et al., 2015). The prevalence of cancer,
especially cancers speciﬁc to women, is growing worldwide. Approxi-
mately 13 percent of women around the world are diagnosed with
various types of gynecologic cancers (Zhou et al., 2015).
Receiving any cancer diagnosis is an unpleasant experience,
wrought with distress, which impacts a person's personal and family life
(Soleimani et al., 2017). As a result of diagnosis, patients experience
socio-economic problems, marital issues, and psychological problems
(Brunault et al., 2016; Wilson et al., 2016). Intense psychological dis-
tress is common not only upon receiving a diagnosis, but also
throughout treatment (Staﬀord and Miller, 2014). Patients experience
anger, depression, pain, and suﬀering as a result of the gynecologic
cancer. Physical consequences of cancer, such as impaired body image,
hair loss, and removal of female sex organs, as well as psychological
consequences of cancer, such as death anxiety, can aﬀect sexuality
(Benedict et al., 2016a; Hasanvand et al., 2015).
Changes in sexual function is a common complication of gyneco-
logic cancer and related treatments (Hopkins et al., 2015). For example,
a systematic review in 2016 shows that Female Sexual Dysfunction
(FSD) prevalence was higher than 60% at all cancer sites, with the
highest value for gynecological cancer. In addition, women with cancer
showed low FSFI scores with a high prevalence of FSD (Maiorino et al.,
2016). In women, sexual function is divided into six components in-
cluding 1) the desire to engage in sexual activity 2) sexual arousal (i.e.
physiological responses as a result of stimulation of sexual organs) 3)
lubrication following sexual stimulation 4) orgasm 5) sexual
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satisfaction and 6) pain (i.e. frequency and amount of vaginal pain
during intercourse; (Rosen et al., 2000). Women with ovarian cancer
experience a reduction in estrogen and androgens, resulting in vaginal
dryness, thinning of the vagina and vulva tissues, loss of vaginal elas-
ticity, and hot ﬂashes (Michael and O'Keane, 2000). In addition, a
persistent lack of sexual interest and lubrication has been reported in
this population (Carter et al., 2005; Jensen et al., 2003). Aside from the
cancer itself, treatment also has an impact on sexual function. Women
with gynecologic cancer who received radiotherapy had more problems
with sexual desire and arousal compared to those who received another
treatment (Stage, 1989). In another study, researchers found that pa-
tients who underwent a radical hysterectomy experienced severe or-
gasmic problems and uncomfortable sexual intercourse due to reduced
vaginal size, severe dyspareunia, and sexual dissatisfaction (Jensen
et al., 2004). Thus, sexual function in patients with gynecological
cancer is impaired.
Sexual distress is a broad term encompassing any sexual discomfort
and dysfunction and includes decreased libido, diﬃculty achieving
orgasm, dyspareunia, vaginal dryness, and vaginismus. In fact, sexual
distress can cause stress and anxiety in individuals (Kadkhodaian et al.,
2015). Researchers have found that sexual distress is present in all
stages of treatment and during follow up in patients with gynecologic
cancer (Kadkhodaian et al., 2015; Oskay et al., 2011; Pinto, 2013; Plotti
et al., 2012). Despite this, sexual distress is undertreated in patients
with gynecological cancer (Plotti et al., 2012). Few researchers have
investigated the factors underlying sexual distress in these patients
(Colson et al., 2006; Hawton et al., 1994; Maughan and Clarke, 2001).
An exception is a study by (Pazmany et al., 2013), who showed that
cognitions about one's own vaginal penetration, body image and genital
self-image each contributed independently to the variance in sexual
distress in Premenopausal women.
From the few studies investigating factors that contribute to sexual
distress, we see that patients with gynecological cancer experience
physical, mental and economic changes, which all contribute to sexual
distress (Fernandes, 2009; Raggio et al., 2014; Tojal and Costa., 2015).
These changes can lead to sexual dissatisfaction not only in patients, but
in their spouses as well (Woertman and van den Brink, 2012; Ye et al.,
2014). Sexual dissatisfaction has a direct impact on the quality of life of
patients, and it reduces the quality of their sexual relationships (Fahami
et al., 2014). Impaired sexual function is also a factor that contributes to
sexual distress in women with gynecologic cancer(Plotti et al., 2012).
Sexual distress also impacts the mental health of the patient
(Michael and O'Keane, 2000; Pinto, 2013). In fact, sexual distress may
lead to anger and aggression, separation, divorce, depression and other
mental health problems (Mazinani et al., 2013). The negative eﬀects on
patients' mental health in turn impacts the relationship between
spouses, which in turn can negatively impact sexual satisfaction and
can lead to sexual dysfunction (Lau et al., 2006). Health care providers,
however, pay more attention to the survival of the patient, controlling
the signs and symptoms of disease and physical symptoms of patients,
and do not often address the mental health of patients (Javadi et al.,
2010; Paterson et al., 2015).
Although extensive research has substantiated that patients with
cancer report lowered sexual satisfaction and sexual function, and high
psychological distress (Benedict et al., 2016b; Wettergren et al., 2017),
there has been limited research investigating sexual distress and sexual
function among patients with gynecologic cancer (Staﬀord and Miller,
2014). Further, although factors such as age, sex, socioeconomic status,
and health have been shown to impact sexual function and the ex-
perience of distress (Jackson et al., 2016; Rottmann et al., 2017), little
is known about relations of these factors to sexual function and distress
in women with cancer speciﬁcally (Fahami et al., 2014). Even less in
known about factors associated with sexual function and sexual distress
among Iranian patients with gynecologic cancer, who are a part of a
culture dominated by Islamic religious and social practices. The pur-
pose of this exploratory study was to examine the relations between
sexual distress and sexual function among Iranian patients with gyne-
cologic cancer who are receiving or preparing for anticancer treatment.
Further, we examined if sociodemographic factors (age, education, and
socioeconomic status), health factors (cancer stage, type of cancer, type
of treatment received, and time lapse since diagnosis), were associated
with sexual distress and sexual function in this sample of Iranian
women with gynecologic cancer.
2. Methods
2.1. Study design and participants
A descriptive cross-sectional correlational design was used to ex-
amine the relationship between sexual distress and sexual function. A
convenience sampling approach was adopted to collect the data of
gynecologic cancer patients who were referred to the oncology clinic of
Velayat Hospital in Qazvin, Iran, between June and August 2016. To
determine adequate sample size, we chose the Cohen approach (Cohen,
1988; Cohen et al., 2003). The Cohen approach evaluates both the re-
lative and absolute values of the changes between groups and allows
statistical analyses. The sample size necessary was 387, with an
α=0.05, power= 0.80 (β=0.20), and eﬀect size (d=0.3). During
the above-mentioned time period, 506 patients were referred to the
study. Of these patients, 468 patients fulﬁlled inclusion criteria, and
387 patients were recruited with an overall survey response rate of
82.6%.
In order to be eligible to participate in this study, participants had to
1) have a conﬁrmation of a gynecologic cancer and it's stage, 2) be
between the ages of 20–65, 3) be aware of the disease, and 4) have the
ability to communicate with researcher. The experience of any sexual
distress before being diagnosed the cancer was considered an exclusion
criteria.
2.2. Instruments
Participants completed a questionnaire which consisted of three
parts: 1) Basic questions regarding demographics, 2) the Female Sexual
Function Index (FSFI) and 3) the Female Sexual Distress Scale-Revised
(FSDR). The demographic portion of the questionnaire collected in-
formation about each patients’ age, age at marriage, length of marriage,
duration of marriage, educational level, economic status, number of
children, duration of the disease, stage of the cancer based on pathol-
ogist report, and type of treatment. Social support was measured by an
analogue scale ranging from 0 to 10 (0=no social support to
10= suﬃcient/adequate/lots of social support).
2.2.1. Female Sexual Distress Scale-Revised (FSDS-R)
This is a self-report questionnaire designed by Derogatis et al.
(2008). It consists of 13 items assessing diﬀerent aspects of sexual ac-
tivity-related distress in women. All items are scored on a ﬁve-point
Likert-type scale ranging from 0 (never) to 4 (always), with a higher
score indicating more sexual distress (Derogatis et al., 2008). The va-
lidity and the reliability of FSDS-R have been well established in Iranian
population (Azimi Nekoo et al., 2014; Ghassami et al., 2014). In our
sample, Cronbach's alpha for the FSDS-R was 0.86 indicating good in-
ternal consistency.
2.2.2. Female Sexual Function Index (FSFI)
This questionnaire was designed by Rosen et al. (2000). It consists
of 19 items that cover 6 domains of women's sexual functioning in-
cluding sexual desire (items 1, 2), arousal (items 3,4,5,6), lubrication
(items 7,8,9,10), orgasm (items 11,12,13), satisfaction (items
14,15,16), and pain (items 17,18,19). All items are scored on a Likert-
type scale ranging from 0 (or 1) to 5, with higher scores indicating
better sexual functioning (Rosen et al., 2000). The validity and the
reliability of FSFI have been previously well established (Hasanzadeh
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Mofrad et al., 2015; Karamidehkordi and Roudsari, 2014). In this
sample, Cronbach's alpha for FSFI was 0.82.
2.3. Ethical considerations
Our study was approved by our main aﬃliated university's medical
sciences ethics committee (No. Ir.QUMS.REC.1394.296). Before signing
an informed consent form, patients were informed about study aims
and procedures, that participation was voluntary, and that participation
would not aﬀect medical care. Patient conﬁdentiality was assured by
completing all study procedures in a quiet treatment area. To ensure
that a broad cross-section of patients were allowed to participate, a
trained research assistant provided support as needed. All personal data
was de-identiﬁed with the use of assigned codes.
2.4. Statistical analysis
The Statistical Package for Social Sciences, version 20.0 (SPSS Inc.,
Chicago, IL, USA) was utilized for data analysis. Descriptive statistics
for continuous variables were means and standard deviations, and were
n (%) for the categorical variables. For the assessment of normality of
two main variables (sexual function and sexual distress), we used the
Kolmogorov-Smirnov (K-S) and Shapiro-Wilk test, with p-value greater
than 0.05, which indicates normal distribution of data. A Pearson cor-
relation analysis was applied to examine the relation between FSFI and
FDS-R. The predictors associated with FSFI and FDS-R scores were de-
termined using general linear models with Bonferroni corrections for
pairwise comparisons. Statistical signiﬁcance was set at p < 0.05 for
all procedures.
3. Results
3.1. Participants' proﬁle
Table 1 describes the demographic proﬁles of the respondents.
Participants were an average of 43.6 years old (SD=8.4,
range= 30–61) and 34.6% (n=134) of the patients were in the ﬁrst
stage of cancer. The respondents predominately suﬀered from breast
cancer (n= 162, 41.9%) and 22% (n=85) of patients received a
combination of therapies.
3.2. Correlational analysis
The mean score for the FSFI was 19.4 (SD=6.7; range=2–31.6).
This score reﬂects low levels of sexual function among the patients with
gynecologic cancer. The mean total score for the sexual distress was
29.2 (SD=12.9; range= 0.0–52.0) which indicated low levels. There
were no signiﬁcant Pearson correlations between FSDS-R total and FSFI
total scores, nor between FSDS-R and any of the FSFI sub scales
(Table 2).
3.3. Predictors of Sexual Function (using the FSFI)
Multivariate predictors of FSFI were cancer stage, cancer type,
duration of disease & social support. Subjects with cancer stage IV
(p=0.023) and having multiple types of cancer (breast/cervical &
breast/ovarian; (p=0.025) displayed the lowest FSFI. We found a
negative relation between duration of disease and FSFI score
(β=−0.10, 95% CI [-0.17, – 0.02], p=0.017) and a positive relation
between social support and FSFI score (β=0.53, 95% CI [0.24, 0.83],
p < 0.001) and a trend positive relation (p=0.063) between type of
treatment Chemo & Radiation and FSFI score (see Table 3).
3.4. Predictors of Sexual Distress (using the FSDS-R)
Multivariate predictors for FSDS-R were economic status, cancer
type, and the desire and arousal subscales of the FSFI. Patients with
good/very good economic status had higher FSDS-R scores compared to
the patients with poor and average economic status (p=0.040).
Patients with breast/cervical and breast/ovarian cancers had lower
FSDS-R scores compared to patients with a single cancer (p=0.016).
We found negative relations between FSDS-R scores and the FSFI sub-
scales for desire (β=−1.4, 95% CI [-0.26,−0.12], p=0.033) and for
arousal (β=−2.1, 95% CI -3.9 to −0.28, p=0.024) (see Table 4).
Table 1
Demographic characteristics of the Married study participants (n=387).
Demographic characteristics Number (%)
Educational status No formal education 44 (11.4)
Primary 65 (16.8)
Intermediate 94 (24.3)
High School 96 (24.8)
Collegiate 88 (22.7)
Economic Status Poor 114 (29.5)
Average 156 (40.3)
Good 95 (24.5)
Very Good 22 (5.7)
Stage of Cancer I 134 (34.6)
II 138 (35.7)
III 83 (21.4)
IV 32 (8.3)
Type of Cancer Breast 162 (41.9)
Ovary 67 (17.3)
Uterus 150 (38.8)
Breast and Cervical Cancer 5 (1.3)
Breast and Ovarian Cancer 3 (0.8)
Type of treatment Treatment undecided or not
started
6 (1.6)
Chemo therapy 70 (18.1)
Radiation therapy 13 (3.4)
Combination (Chemo and
Radiation) therapies
85 (22.0)
Surgery 2 (0.5)
Multiple treatment 211 (54.5)
Mean (SD), range
Age years 43.6 (8.4), 30-61
Marriage age 19.4 (5.4), 9-42
length of marriage months 23.9 (10.9), 2-52
Number of children 2.9 (2.1), 0-12
Time Duration of
disease
months 14.3 (9.2), 1-48
Social Support 4.1 (2.3), 0-10
FSFI Total score of FSFI 19.4 (6.7), 2–31.6
Desire Subscale of FSFI 3.1 (1.2), 1.2–6.0
Arousal Subscale of FSFI 3.1 (1.3), 0.0–5.1
Lubrication Subscale of FSFI 3.1 (1.3), 0.0–6.0
Orgasm Subscale of FSFI 3.2 (1.4), 0.0–6.0
Satisfaction Subscale of FSFI 3.5 (1.6), 0.8–6.0
Pain Subscale of FSFI 3.4 (1.7), 0.0–6.0
FSDS-R Total score of FDS-R 29.2 (12.9),
0.0–52.0
Table 2
Correlation between FSFI and FSD-R.
Spearman's Correlations with FSD-R
Desire 0.007 (p=0.885)
Arousal −0.106 (p=0.370)
Lubrication 0.012 (p=0.821)
Orgasm 0.083 (p=0.101)
Satisfaction 0.082 (p=0.105)
Pain −0.046 (p=0.367)
FSFI 0.023 (p=0.648)
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4. Discussion
This study was conducted in order to examine the relation between
sexual distress and sexual function, and the factors predicting these two
constructs, in Iranian patients with gynecologic cancer. We did not ﬁnd
any signiﬁcant relation between sexual distress and sexual function or
the subscales of sexual distress. This is in contrast with previous ﬁnd-
ings. For example, Fritzer et al. (2013) reported a positive relationship
between these variables in endometriosis patients (Fritzer et al., 2013).
Bjerggaard et al. (2015) have also studied sexual distress and sexual
function among peoples with Type 2 Diabetes and reported a positive
correlation between these variables (Bjerggaard et al., 2015). More-
over, the results of one study indicated that high sexual distress is ac-
companied by experiencing low sexual function among middle-aged
women (Dennerstein et al., 2008). It seems that individuals with im-
paired sexual function are more likely to have diﬃculty preserving,
restoring or improving their sexual well-being (Rosato et al., 2014).
Focusing on other values, for example children or family, may distract
patients and draw their attention away from their sex-related problems.
This can be considered as the possible reason of not ﬁnding relations.
Our study revealed a negative relation between cancer stage and
sexual function score. A study investigating women with cervical cancer
and a history of pelvic radiation therapy in Iran supports these ﬁnding
(Hasanzadeh Mofrad et al., 2015), while another study in breast cancer
survivors and healthy women did not ﬁnd a signiﬁcant correlation
among these variables (HY et al., 2009). In another study, women's
sexual satisfaction, capacity for orgasm, and frequency of masturbation
remained stable after cancer therapy whereas frequency of sexual ac-
tivity with a partner and range of sexual practices decreased sig-
niﬁcantly after one year (Stage, 1989). These results show that the
patients with more advanced stages of cancer will experience more
problems in their sexual relationships. Patients with cancer experience
emotional disturbances such as loss of femininity, loss of physical at-
tractiveness, among others (Begovic-Juhant et al., 2012; Spiegel and
Nemeroﬀ, 1997). These feelings aﬀect patients physically, psychologi-
cally and socially in a vicious circle. Most patients with gynecologic
cancer are of childbearing age, and may have concerns and distress
related to loss of fertility, which aﬀects sexual function (Reis et al.,
2010; Sacerdoti et al., 2010). Cancer also inﬂuences a patient's sub-
sequent experiences in all aspects of life, especially her sexual life.
Therefore, sexual function will be impaired over time (Khajehaminian
et al., 2014).
The current study also indicates that patients with concurrent
breast/cervical or breast/ovarian cancer report the lowest FSFI scores.
In the case of simultaneous gynecological cancers, problems are mul-
tiplied. Treatment of one of the cancers impacts the performance of
other female organs. For example, patients with breast cancer have
problems with body image (Fobair et al., 2006). When a patient con-
currently has cervical cancer, she will experience problems on the
genital tract which can directly aﬀect the sexual function (Jensen et al.,
Table 3
Predictors of Sexual Function (using the FSFI).
Demographic characteristics FSFI Mean (SD) Unadjusted p-value Adjusted p-value
Educational status No formal education 16.4 (8.2) 0.002 0.389
Primary 18.0 (7.5)
Intermediate 20.4 (5.2)
High School 20.4 (5.5)
Collegiate 19.9 (7.1)
Economic Status Poor 17.5 (7.2) 0.001 0.118
Average 19.6 (6.6)
Good 20.6 (5.8)
Very Good 22.5 (5.4)
Stage of Cancer I 20.8 (5.8) 0.002 0.023
II 19.0 (6.6)
III 19.3 (6.7)
IV 15.9 (8.7)
Type of Cancer Breast 19.4 (6.8) 0.005 0.025
Ovary 19.5 (6.2)
Uterus 19.9 (6.3)
Breast and Cervical Cancer 13.8 (11.2)
Breast and Ovarian Cancer 7.0 (8.7)
Type of treatment Treatment undecided or not started 19.8 (8.8) 0.111 0.063
Chemo therapy 19.6 (6.5)
Radiation therapy 19.7 (5.9)
Combination (Chemo and Radiation) therapies 21.2 (4.9)
Surgery 16.5 (19.6)
Multiple treatment 18.7 (7.1)
b (95% CI) b (95% CI)
Age Age of subject – −0.13 (−0.21 to – 0.06)
p= 0.001
−0.03 (−0.26 to 0.21)
p= 0.828
Marriage age Age of Marriage – 0.08 (−0.04 to 0.20)
p= 0.197
−0.03 (−0.26 to 0.20)
p= 0.759
length of marriage Duration of Marriage – −0.10 (−0.16 to – 0.04)
p= 0.001
−0.03 (−0.29 to 0.18)
p= 0.793
Number of children Number of Participants' Children – −0.50 (−0.82 to – 0.18)
p= 0.002
−0.21 (−0.59 to 0.29)
p= 0.291
Time Duration of disease Duration of the Disease – −0.12 (−0.20 to – 0.05)
p= 0.001
−0.10 (−0.17 to – 0.02)
p= 0.017
Social Support Social Support of subjects – 0.70 (0.42–0.98)
p < 0.001
0.53 (0.24–0.83)
p < 0.001
FSDS.R Total Score – 0.02 (−0.03 to 0.07)
p= 0.451
−0.02 (−0.08 to 0.03)
p= 0.371
Abbreviation: SD: standard deviation; b: regression estimate; CI: Conﬁdence Interval.
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2003). The results of Bergmark et al. (1999) revealed that vaginal
changes due to cervical cancer and treatments would aﬀect sexual
function at least as much as the loss of a breast. An obvious reason for
the predominant interest in the breast is that, in developed countries,
breast cancer is more common than cancer of the female genital organs
(Bergmark et al., 1999).
The current study also found that duration of cancer had a negative
relation with FSFI scores. This is in contrast to ﬁndings by Lui et al.
(2015), who found that duration of the illness was not a signiﬁcant
predictor of sexual dysfunction among Filipinas with breast cancer (Lui
et al.). Diagnosis of cancer can be very distressing to some patients
because they may experience direct or indirect sexual side eﬀects of
treatment such as disturbances of arousal, dyspareunia, vaginal ste-
nosis, among others. Patients may worry that sexual intercourse will
further injure their diseased sexual organ, or lead to cancer recurrance,
as long as the survival period is not over (Tee et al., 2014).
The ﬁndings of the present study also emphasized that FSFI has a
positive relationship with social support. Pieterse et al. (2013) and
Milbury et al. (2013) supported these ﬁnding (Milbury et al., 2013;
Pieterse et al., 2013). However, Tee et al. (2014) did not ﬁnd a sig-
niﬁcant relation between these variables (Tee et al., 2014). Social
support is deﬁned as support provided by family members, colleagues
and other friends (Tasdan and Yalcin, 2010). Those who receive social
support feel that others love them, and have a sense of importance.
They feel that others respect them, and they know they are a part of
family and friend network or social organization, which can be the
source of monetary and moral help (Alizadeh et al., 2016). Therefore,
having support services may facilitate dealing with the problems re-
lated to having cancer. For example, connecting with friends and others
can help patients to share their concerns and experiences with others,
Table 4
Predictors of sexual distress (using the FSDS-R).
Demographic characteristics FDSR Mean (SD) Unadjusted p-value Adjusted p-value
Educational status No formal education 24.7 (13.8) 0.001 0.437
Primary 28.8 (12.4)
Intermediate 27.9 (12.6)
High School 28.4 (12.4)
Collegiate 33.9 (12.4)
Economic status Poor 25.9 (12.8) < 0.001 0.040
Average 28.6 (13.1)
Good 33.5 (11.4)
Very Good 31.8 (14.7)
Stage of cancer I 31.2 (13.14) 0.058 0.429
II 28.8 (13.12)
III 26.4 (11.46)
IV 29.7 (14.50)
Type of cancer Breast 27.6 (12.4) 0.005 0.016
Ovary 27.8 (14.1)
Uterus 32.0 (12.5)
Breast and Cervical Cancer 19.6 (8.1)
Breast and Ovarian Cancer 20.1 (3.1)
Type of treatment Treatment undecided or not started 31.5 (14.9) 0.221 0.344
Chemo therapy 30.2 (12.9)
Radiation therapy 25.8 (14.4)
Combination (Chemo and Radiation) therapies 31.6 (13.0)
Surgery 35.0 (7.1)
Multiple treatment 27.9 (12.6)
b (95% CI) b (95% CI)
Age Age of subject – −0.27 (−0.42 to – 0.12)
p= 0.001
−0.33 (−0.79 to – 0.13)
p= 0.156
Marriage age Age of Marriage – 0.23 (−0.01 to 0.46)
p= 0.058
0.22 (−0.22 to 0.65)
p= 0.334
length of marriage Duration of Marriage – −0.19 (−0.31 to – 0.07)
p= 0.002
0.28 (−0.23 to – 0.78)
p= 0.281
Number of children Number of Participants' Children – −0.86 (−1.5 to – 0.24)
p= 0.007
−0.23 (−1.0 to 0.53)
p= 0.548
Time Duration of disease Duration of the Disease – −0.11 (−0.25 to 0.03)
p= 0.109
−0.04 (−0.20 to 0.12)
p= 0.596
Social Support Social Support of subjects – 0.42 (−0.15 to 0.98)
p= 0.145
0.22 (−0.38 to 0.83)
p= 0.470
FSFI Total Score – 0.07 (−0.12 to 0.27)
p= 0.451
−0.09 (−0.30 to 0.11)
p= 0.371
Adjusted for above demo variables
Desire Subscale of FSFI – 0.04 (−1.0 to 1.1)
p= 0.943
−1.4 (−0.26 to −0.12)
p= 0.033
Arousal Subscale of FSFI – −0.11 (−1.1 to 0.9)
p= 0.830
−2.1 (−3.9 to −0.28)
p= 0.024
Lubrication 0.35 (−0.63 to 1.3)
p= 0.482
0.60 (−1.9 to 3.1)
p= 0.638
Orgasm Subscale of FSFI – 0.78 (−0.15 to 1.7)
p= 0.101
1.1 (−1.5 to 3.7)
p= 0.429
Satisfaction Subscale of FSFI – 0.71 (−0.08 to 1.5)
p= 0.077
0.15 (−1.3 to 1.6)
p= 0.841
Pain Subscale of FSFI – −0.20 (−0.97 to 0.56)
p= 0.600
0.18 (−1.0 to 1.4)
p= 0.770
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especially with peers. These resources can act as a buﬀer and reduce the
patient's distress.
The current study also found that type of treatment (chemo and
radiation therapies) had a correlation with FSFI scores. Similar to our
results, previous studies indicated that patients with gynecologic and
breast cancers who had chemo and radiation therapy reported higher
FSFI (Fahami et al., 2014; Hendren et al., 2005). However, other re-
searchers found conﬂicting results (Capogrosso et al., 2016; Dickson
et al., 2015). It seems that treatments such as radiotherapy and che-
motherapy in gynecologic cancer causes damages to the genital system
and the organs around it. Vaginal stenosis, reduction in vaginal lu-
brication, and lack of orgasm are among the eﬀects of radiotherapy and
chemotherapy which may inﬂuence the sexual function (Fahami et al.,
2014).
Other important study ﬁndings include that women with good/very
good economic status showed a higher FSDS-R score. Colson et al.
(2006) showed that socio-economic status is one of the factors that is
related to FSDS-R scores (Colson et al., 2006). In contrast, another study
on middle-aged women revealed that there was a weak positive cor-
relation between higher socioeconomic status and sexual enjoyment of
sexual activity (Hawton et al., 1994). A study by Ansong et al. (2000)
on men reported that erectile dysfunction was more common in persons
who have poor/very poor economic status (Ansong et al., 2000). In our
study, it seems that the cost of cancer diagnosis and treatment for
subjects who have good economic status is challenging and can be a
reason for concern for these people especially if patients don't have
adequate insurance coverage.
Suﬀering from multiple cancers was another factor that predicted
FSDS-R scores. Speciﬁcally, women with breast/cervical and breast/
ovarian cancer reported lower FSDS-R compared to who had only one
type of cancer. Maybe women with one type of cancer are also at an
earlier stage of cancer (and have had relatively less time to process their
emotions) and women with multiple cancers are at a later stage (and
have had time to come to terms with their diagnosis). In addition,
maybe the women with multiple cancers are on stronger medications,
which reduces their distress compared to women with only one type of
cancer. Some studies showed that patients with gynecologic disease,
including cancer, are vulnerable to sexual distress (Maughan and
Clarke, 2001). Cancer diagnosis and the related stress can have a deep
eﬀect on sexual function. This is especially the case for women with
breast cancer who lose their femininity. Impaired self-concept relating
to sexuality in both gynecologic and breast cancer will inﬂuence on the
severity of sexual function and experience of sexual distress (Fahami
et al., 2014; Lindau et al., 2015).
The desire and arousal subscales of FSFI were negatively associated
with the FSDS-R. Studies on Caucasian women with healthy popula-
tions and cancer patients show similar results (Brotto et al., 2008;
Brotto and Heiman, 2007; Stephenson et al., 2012; Stephenson and
Meston, 2012). Impairments in sexual desire and arousal can impact
woman's sexual experiences in a number of ways including, but not
limited to, decreasing her physical pleasure during sex, preventing or
disrupting sexual activity, and engendering negative partner responses
during sex. These consequences of impaired sexual function are likely
highly distressing to the individual in many cases, possibly even more
so than the impaired functioning itself (Stephenson and Meston, 2012).
4.1. Limitations
Some of the major limitations of our study were the cross sectional
design of the study and convenience sampling procedure, which limits
the generalizability of the research ﬁndings. Although our sample size is
adequate according to a power calculation, a larger number of women
are needed to increase the information about the sexual function and
sexual distress in groups of women with diﬀerent cancers. When in-
terpreting our results, the sample size should be considered, with stu-
dies with larger sample insigniﬁcant diﬀerence may become
statistically signiﬁcant. Another weak point was the lack of data about
frequency of sexual intercourse, fantasies, masturbation and quality of
sexual relationship. Moreover, the sample was taken from a hetero-
geneous group of patients with diﬀerent stages and treatments for
cancer at varying points in the illness trajectory. Finally, one of the
limitations of self-report in general is that there is always the potential
that social desirability will contribute to how participants answered
questions.
5. Conclusion
This study did not support the relation between sexual distress and
sexual function among a sample of Iranian women with gynecologic
cancer. However, the results showed that sexual function and sexual
distress are related to many elements including cancer type, economic
status and level of social support received. Future studies need to
clearly determine the exact relation between FSFI and FSDS-R in spe-
ciﬁc types of cancer, and to uncover other unknown factors aﬀecting
the sexual distress and sexual function of women with gynecological
cancer.
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